Several other mRNA products have also shown promise, such as ECI-006, a combination of TriMix and melanoma-specific TAAs administered intranodularly and being tested in a phase 1 study of resected melanoma (NCT03394937); and MEDI1191, an immunomodulatory fusion protein containing IL-12α and IL-12β subunits developed for intratumoral injection (Wang et al., 2023). Here, IL12B is linked to melanoma.